ITOS ITeos Therapeutics
- 16.230
- -0.070-0.43%
- 16.230
- 0.0000.00%
ITeos Therapeutics News
J.P. Morgan Maintains ITeos Therapeutics(ITOS.US) With Buy Rating
J.P. Morgan analyst Brian Cheng maintains $ITeos Therapeutics(ITOS.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 31.2% and a total average return of -18.7% over
We Think ITeos Therapeutics, Inc.'s (NASDAQ:ITOS) CEO Compensation Package Needs To Be Put Under A Microscope
Key Insights iTeos Therapeutics to hold its Annual General Meeting on 11th of June Total pay for CEO Michel Detheux includes US$578.9k salary The total compensation is 38% higher than the average
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
ITeos Therapeutics (NASDAQ:ITOS): Harnessing the Power of Immunotherapy
Merck Discontinues Testing of Experimental Skin Cancer Combo Therapy
ITeos Therapeutics Is Maintained at Buy by HC Wainwright & Co.
ITeos Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on ITeos Therapeutics, Raises Price Target to $46
ITeos Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 156.98% HC Wainwright & Co. $44 → $46 Maintains Buy 03/12/2024 50.84% JP Morgan $29 → $27 Maint
ITeos Therapeutics Shares Surge 47% After Promising Tumor Treatment Data
By Ben Glickman Shares of iTeos Therapeutics rose sharply after the company said one of its tumor treatment clinical trials had shown promising interim results. The stock was up 47% to $17.86 in Fri
Riding High: ITeos Therapeutics' (ITOS) Stock Surges Amid Market Activity
Following the dissemination of a corporate update and financial appraisal, the stock of iTeos Therapeutics, Inc. (NASDAQ: ITOS) has experienced a surge in value during the present trading session. At the latest market evaluation, ITOS shares demonstrated an increase of 46.31% on the US stock exchanges, reaching $17.83. Clinical Advancements: Promising Developments In GALAXIES Lung-201 ...
ITeos Therapeutics Up Over 46%, On Track for Record Percent Increase -- Data Talk
iTeos Therapeutics, Inc. (ITOS) is currently at $17.81, up $5.62 or 46.1% --Would be highest close since May 26, 2023, when it closed at $18.05 --Would be largest percent increase on record (Based o
NVAX, GRPN and MVIS Among Mid-day Movers
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results.Diodes posted adjusted earnings of 28 cents
12 Health Care Stocks Moving In Friday's Intraday Session
GainersNovavax (NASDAQ:NVAX) stock increased by 110.7% to $9.42 during Friday's regular session. The market value of their outstanding shares is at $1.3 billion. The company's, Q1 earnings came out to
Express News | Iteos Therapeutics Inc : Wedbush Raises Target Price to $21 From $18
Genpact Posts Upbeat Earnings, Joins Groupon, Natera, Funko, CarGurus And Other Big Stocks Moving Higher On Friday
U.S. stocks were mostly higher, with the Dow Jones gaining over 100 points on Friday.
Novavax, Macrogenics, Biofrontera Among Healthcare Movers
Market-Moving News for May 10th
ITOS: 39% | iTeos Therapeutics shares are trading higher after the company announced a $120 million registered direct offering and reported Q1 financial results.NVAX: 100% | Novavax shares are trading
ITeos Therapeutics | 10-Q: Quarterly report
Express News | ITeos Therapeutics Shares Are Trading Higher After the Company Announced a $120 Million Registered Direct Offering and Reported Q1 Financial Results
Analysis
Price Target
No Data
